Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $6.3 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.